Exhibit 5.2
| | |
19 May 2023 | | We do not accept service of court documents by fax |
BY EMAIL
No. of pages: 14 (excluding enclosures)
Pfizer Investment Enterprises Pte. Ltd.
c/o Pfizer Inc
66 Hudson Boulevard East
New York, NY 10001
Dear Sirs,
Pfizer Investment Enterprises Pte. Ltd. (Company Reg. No.: 202315648E) (Company) – Legal Opinion in respect of the Note Certificates
1.1 We have acted as advisers as to Singapore law to the Company in connection with the issuance and sale of $3,000,000,000 aggregate principal amount of 4.650% Notes due 2025, $3,000,000,000 aggregate principal amount of 4.450% Notes due 2026, $4,000,000,000 aggregate principal amount of 4.450% Notes due 2028, $3,000,000,000 aggregate principal amount of 4.650% Notes due 2030, $5,000,000,000 aggregate principal amount of 4.750% Notes due 2033, $3,000,000,000 aggregate principal amount of 5.110% Notes due 2043, $6,000,000,000 aggregate principal amount of 5.300% Notes due 2053 and $4,000,000,000 aggregate principal amount of 5.340% Notes due 2063 (collectively, Debt Securities) of the Company, which are guaranteed on a unsecured basis (Guarantee) by Pfizer Inc., a Delaware corporation (Guarantor). The Debt Securities will be issued pursuant to the Indenture, dated as of 19 May 2023 (Base Indenture), among the Company, the Guarantor and The Bank of New York Mellon, as trustee (Trustee), and the First Supplemental Indenture, dated as of 19 May 2023, among the Company, the Guarantor and the Trustee (First Supplemental Indenture, together with the Base Indenture, Indenture). On 16 May 2023, the Company entered into an Underwriting Agreement, dated as of 16 May 2023 (Underwriting Agreement), and related Pricing Agreement, dated as of 16 May 2023 (Pricing Agreement), with the Guarantor and the underwriters named in Schedule 1 of the Pricing Agreement (Underwriters), relating to the sale by the Company to the Underwriters of the Debt Securities. The Underwriting Agreement, the Pricing Agreement, the Indenture and Note Certificates (as defined in Schedule 1) are referred to herein collectively as the Transaction Agreements.
1.2 This opinion is being furnished to you in connection with the filing of the registration statement on Form S-3ASR (File No. 333-253605) of the Company relating to the Debt Securities and other securities of the Company filed with the Securities and Exchange Commission (Commission) on 26 February 2021 under the Securities Act of 1933, as amended (Securities Act), allowing for delayed offerings pursuant to Rule 415 of the General Rules and Regulations under the Securities Act (Rules and Regulations) as amended by Post-Effective Amendment No. 1 thereto, filed with the Commission on 15 May 2023, including information deemed to be a part of the registration statement pursuant to Rule 430B of the Rules and Regulations (such registration statement being hereinafter referred to as the Registration Statement).
DREW & NAPIER LLC 10 Collyer Quay, #10-01 Ocean Financial Centre, Singapore 049315
T:+65 6535 0733 T:+65 9726 0573 (After Hours) F:+65 6535 4906 E: mail@drewnapier.com www.drewnapier.com
Drew & Napier LLC (UEN 200102509E) is a law corporation with limited liability.